Surprisingly Useful AI Article Enhancements
Expanding Access To Medical Physics And Radiation Detection
Device Technologies has acquired DTect Innovation, a provider of medical physics and radiation detection solutions, as part of its strategy to enhance oncology care in Australia.
DTect Innovation supplies products for radiation therapy, diagnostic radiology, nuclear security and environmental management. The acquisition aims to expand access to oncology technologies, ensuring clinicians and patients benefit from advanced medical solutions.
DTect was founded in 2016 by Peter Douglas, who has over 36 years of experience in nucleonic equipment for detection, measurement and radiation delivery. Douglas said the acquisition will enhance support for clinicians, medical physicists and researchers.
“This acquisition allows us to expand our reach and support more professionals delivering critical oncology care. Becoming part of Device Technologies strengthens our ability to provide high-quality products and trusted solutions while improving precision and patient outcomes,” Douglas said.
Strengthening Oncology Capabilities
By integrating DTect’s expertise in dosimetry and medical physics, Device Technologies aims to improve treatment precision and clinician support. The acquisition will expand access to specialist oncology solutions across Australia and New Zealand.
Michael Trevaskis, Chief Executive Of Device Technologies, said the move aligns with the company’s focus on advancing healthcare solutions.
“Acquiring DTect Innovation reinforces our commitment to delivering advanced healthcare solutions across the ANZ region. With over 36 years of expertise in medical physics and radiation detection, DTect is a trusted partner. Integrating its technologies into our portfolio strengthens our ability to support healthcare providers in delivering better patient outcomes and advancing oncology care,” Trevaskis said.
Focus On Broadening Reach In Oncology
Lisa Kirsch, Director Of Sales – Surgical And Hospital Robotic Surgery at Device Technologies, said the acquisition allows the company to expand its role in oncology.
“As we work to impact people’s lives through what we do at Device Technologies, the DTect acquisition represents an opportunity to broaden our reach in the important specialty area of oncology,” Kirsch said.
The acquisition is expected to streamline access to specialist oncology solutions, helping clinicians deliver high-quality care while ensuring medical physics and radiation detection remain a focus in healthcare innovation.
Last Updated on February 22, 2025 by Nick Ross
